Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Hematologic Neoplasms 3Myeloproliferative Disorders 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine phosphate 10Tacrolimus 10Cyclophosphamide 10Busulfan 10Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Antilymphocyte Serum 7Mycophenolic Acid 5Whole-Body Irradiation 4Methylprednisolone 4Etoposide 4thymoglobulin 3Rituximab 3Radiotherapy 3Melphalan 3Cyclosporine 3Sirolimus 2Prednisone 2Filgrastim 2Cytarabine 2Cord Blood Stem Cell Transplantation 2Carmustine 2Alemtuzumab 2ruxolitinib 1merphos 1gamma-Globulins 1fludarabine 1fedratinib 1etoposide phosphate 1carmustine, poliferprosan 20 drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Neutrophilic, Chronic × fedratinib × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡